Novavax

NVAX

Market cap $1.44B

Novavax (NVAX) concluded the recent trading session at $8.84, signifying a +2.31% move from its prior day's close.

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.

In the latest trading session, Novavax (NVAX) closed at $8.53, marking a +1.31% move from the previous day.

The investor, which holds roughly 9% of the company, argued that leadership has failed to translate Novavax's vaccine platform into meaningful commercial success.

Activist investor Shah Capital plans to vote against the re-election of board nominees and the executive ​compensation package at Novavax's upcoming annual meeting, renewing pressure for ‌changes at the vaccine maker.

In the closing of the recent trading day, Novavax (NVAX) stood at $8.02, denoting a -1.47% move from the preceding trading day.

The COVID-19 vaccine boom made fortunes almost overnight—and destroyed them just as fast.

Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Robert Walker, MD, brings more than 30 years in drug and vaccine development and, most recently, served as Novavax's Chief Medical Officer Dr. Walker will continue advancing Novavax's R&D efforts with a focus on data generation to facilitate partnering discussions, Matrix adjuvant innovation and advancement of the Company pipeline   GAITHERSBURG, Md., March 30, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced the appointment of Dr. Robert Walker, MD, as Executive Vice President and Head of Research & Development (R&D).